TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03565341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4
Description: PiQo4 Laser System for treatment of Melasma
Study: NCT02250469

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with the Axium SCS system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with the Medtronic SCS System
Study: NCT04220580

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: 3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
Study: NCT00099502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 250mcg administered s.c. every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 500mcg administered s.c. every other day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Description: 20 mg administered s.c. once daily.
Study: NCT03007420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Occipital Nerve Block (ONB) using lidocaine and dexamethosone
Description: Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone
Description: Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
Study: NCT01840813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: It is a placebo group
Study: NCT02489149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sector interventions
Description: * Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Comparator: Conventional approach of current public food and nutrition policies.
Study: NCT00777595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 4226 pMDI
Description: Inhaled solution, single supratherapeutic dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled solution, single dose of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablet, oral, 400mg, single dose
Study: NCT04054921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: PTG-300 is a hepcidin Mimetic
Study: NCT03804892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: Participants undergo a 5 minute body scan to determine their body composition.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Body Composition
Description: Participants undergo a 5 minute body scan to determine their body composition.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximal aerobic fitness test
Description: Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
Study: NCT01113931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyline Hyclate tablet
Description: 200 mg tablet, once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibramycin (doxycyline hyclate) capsule
Description: 100 mg capsule, twice daily for 7 days, over-encapsulated
Study: NCT02374463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMBI
Description: Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
Study: NCT01221818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 100mg single dose or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 200mg single dose or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 400mg single dose or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 600 mg single dose or matching placebo
Study: NCT04117412

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Same participants will undergo different one bout of exercise protocols
Study: NCT01909609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAP Documents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Survival Guide

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Parent Survival Guide
Study: NCT03406364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG005
Description: Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy.
Study: NCT01082978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic (USB) Portable Health File
Description: Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paper Portable Health File
Description: Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
Study: NCT02726126

Intervention type: DRUG
Intervention: Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy
Study: NCT02374463

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
Study: NCT02726126

Intervention type: DRUG
Intervention: Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy

Intervention type: DRUG
Intervention: Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy
Study: NCT00967226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: propranolol 0.5 mg/kg orally, 4 per day - 4-6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 1.0 mg/kg orally, 2 per day 4-6 months
Study: NCT03804892

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Maximal aerobic fitness test
Description: Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participants will undergo an OGTT to determine insulin sensitivity.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Participants will undergo an OGTT to determine insulin sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle biopsy
Description: Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Participants will give 16 blood samples, to be assessed for fatty acids in the blood.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
Study: NCT02656394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GL101
Description: Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical gel
Study: NCT02556281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is done for patient with colorectal cancer
Study: NCT01489865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 and mFOLFOX-6
Description: ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
Study: NCT04204850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
Study: NCT02095392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1000/Ca0
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1000/Ca0
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1000/Ca500
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1000/Ca500
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1000/Ca1000
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1000/Ca1000
Description: 22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: all participants consume two weeks before intervention the beverage without phosphate and calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: all participants consume two weeks before intervention the beverage without phosphate and calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: all participants consume two weeks before intervention the beverage without phosphate and calcium
Study: NCT00190333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram
Study: NCT04544735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Physical Therapy and Coping Skills Training
Description: The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
Study: NCT00451958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 80 mg / Degarelix 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 160 mg / Degarelix 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide 7.5 mg / Degarelix 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide 7.5 mg / Degarelix 160 mg
Study: NCT01968538

Intervention type: RADIATION
Intervention: Radiation Therapy
Study: NCT01777048

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids Supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Placebo
Description: Placebo capsules manufactured to mimic Omega-3 capsules
Study: NCT00932035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node dissection
Description: Undergo reverse mapping-guided axillary lymph node dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosulfan blue based lymphatic mapping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosulfan blue based lymphatic mapping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection
Description: Undergo standard axillary lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT02662426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lingdancao granules
Description: 4 packs per time (3g/pack), three times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: analogous oseltamivir phosphate capsule
Description: 1 capsule per time, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: analogous oseltamivir phosphate capsule
Description: 1 capsule per time, twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir phosphate capsule
Description: 1 capsule per time (75mg), twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: analogous Lingdancao granules
Description: 4 packs per time, three times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: analogous Lingdancao granules
Description: 4 packs per time, three times per day
Study: NCT01575808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP1101
Description: Endovascular stent graft implantation
Study: NCT05174338

Intervention type: OTHER
Intervention: Registry
Description: Observational, data collection
Study: NCT01527045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT01235663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advisory support
Description: regular advisory support to the prolong breast-feeding period
Study: NCT03569358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality
Description: The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG headband
Description: The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG headband
Description: The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG headband
Description: The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
Study: NCT00418730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
Study: NCT04738994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein-enriched nutritional supplement
Description: Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard hospital diet
Study: NCT01621984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Riding/ Hippotherapy Intervention
Description: The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
Study: NCT00816010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone contact
Description: for lifestyle and compliance counseling
Study: NCT04587206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO